Arr! Ye scallywags, we be findin' no boost for this breast cancer type from chemo, aye!
2023-12-28
Yarr! Mixin' chemotherapy with endocrine therapy for lasses with ER-positive, HER2-negative invasive lobular carcinoma be not boostin' their chances of survival, says Medscape Medical News.
In a quirky twist of events, it seems that adding chemotherapy to endocrine therapy for women with ER-positive, HER2-negative invasive lobular carcinoma doesn't really do much to improve survival outcomes. Arrr, matey! That be a surpirse for all ye landlubbers!Now, ye may be wonderin' what this means for ye, especially if ye happen to be a lass with such a condition. Well, fear not, for I shall break it down for ye in the simplest of terms. Invasive lobular carcinoma be a type of breast cancer, and ER-positive means that it be fueled by estrogen. So, the idea was to give these ladies endocrine therapy to block the estrogen and starve the cancer, and then add chemotherapy to finish it off, much like a cannonball blastin' through the enemy's ship.
But alas, it seems that the addition of chemotherapy be like firing blanks from a flintlock pistol. It don't really make a difference in terms of survival outcomes. Aye, ye heard me right! All those side effects and discomfort that come with chemotherapy, and it don't even give ye a better chance at survivin'. It be like walkin' the plank for no good reason, I tell ye!
Now, don't be gettin' me wrong, matey. This be a serious matter, and I ain't makin' light of the situation. But sometimes, ye gotta find a bit o' humor in the dark stormy seas of life. So, if ye be a lass with ER-positive, HER2-negative invasive lobular carcinoma, ye can rest easy knowin' that ye can skip the chemotherapy and focus on the endocrine therapy, arrr! But always remember to consult yer physician, for they be the ones who can guide ye through these treacherous waters.